{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:52:47Z","timestamp":1791395567800,"version":"4.3.3"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA140198-11-15"],"award-info":[{"award-number":["R01CA140198-11-15"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA230223"],"award-info":[{"award-number":["K08CA230223"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA282041"],"award-info":[{"award-number":["R37CA282041"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-1-0486"],"award-info":[{"award-number":["W81XWH-12-1-0486"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R013208130624"],"award-info":[{"award-number":["R013208130624"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["DP2HD108775"],"award-info":[{"award-number":["DP2HD108775"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA009615"],"award-info":[{"award-number":["5T32CA009615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Braden\u2019s Hope Foundation and the Margaret Q Landenberger Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The <jats:italic>Anaplastic Lymphoma Kinase<\/jats:italic> (<jats:italic>ALK<\/jats:italic>) gene is a receptor tyrosine kinase (RTK) with expression restricted to the developing nervous system. Most neuroblastomas express native ALK protein on the cell surface and ALK is uniformly overexpressed in fusion-positive rhabdomyosarcoma and in subsets of metastatic colorectal carcinoma, melanoma, ovarian carcinoma, and breast carcinoma. Here, we first confirm that <jats:italic>ALK<\/jats:italic> RNA, protein, and tumor cell surface expression is elevated in multiple pediatric and adult malignancies with minimal expression in childhood normal tissues. We then demonstrate that a humanized ALK-directed antibody conjugated to pyrrolobenzodiazepine (CDX0239-PBD) is internalized in ALK-expressing neuroblastoma cell lines with cell surface expression-dependent cytotoxicity. Finally, we show that CDX0239-PBD exhibits potent antitumor efficacy including maintained complete responses in ALK-expressing patient and cell line-derived neuroblastoma, fusion-positive rhabdomyosarcoma, and colorectal carcinoma xenograft models. These data support the clinical development of a first-in-class ALK-directed antibody-drug conjugate (ADC) for multiple pediatric and adult ALK-expressing malignancies.<\/jats:p>","DOI":"10.1038\/s41467-025-62979-1","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:11:11Z","timestamp":1755216671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6789-2652","authenticated-orcid":false,"given":"Alberto D.","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Matkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Acholla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9259-1035","authenticated-orcid":false,"given":"Colleen","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4695-9175","authenticated-orcid":false,"given":"Martina","family":"Mazzeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushbu","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Krytska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9646-8762","authenticated-orcid":false,"given":"Skye","family":"Balyasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6308-142X","authenticated-orcid":false,"given":"Joshua","family":"Kalna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kamitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-4523","authenticated-orcid":false,"given":"Mark","family":"Gerelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-9995","authenticated-orcid":false,"given":"Grace","family":"Polkosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6897-2656","authenticated-orcid":false,"given":"David","family":"Groff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apratim","family":"Mukherje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-4401","authenticated-orcid":false,"given":"Jennifer","family":"Pogoriler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy T.","family":"Spear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-0065","authenticated-orcid":false,"given":"Mattia","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-7929","authenticated-orcid":false,"given":"John M.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-7648","authenticated-orcid":false,"given":"Adam J.","family":"Wolpaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-2858","authenticated-orcid":false,"given":"Kristopher R.","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimiter","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-2821","authenticated-orcid":false,"given":"Mustafa","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dontcho V.","family":"Jelev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-0399","authenticated-orcid":false,"given":"Yael P.","family":"Moss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"62979_CR1","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/cells12131733","volume":"12","author":"MB Santana-Bejarano","year":"2023","unstructured":"Santana-Bejarano, M. B. et al. Pleiotrophin and the expression of its receptors during development of the human cerebellar cortex. Cells 12, 1733 (2023).","journal-title":"Cells"},{"key":"62979_CR2","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nature07261","volume":"455","author":"YP Moss\u00e9","year":"2008","unstructured":"Moss\u00e9, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930\u2013935 (2008).","journal-title":"Nature"},{"key":"62979_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature07398","volume":"455","author":"I Janoueix-Lerosey","year":"2008","unstructured":"Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967\u2013970 (2008).","journal-title":"Nature"},{"key":"62979_CR4","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1038\/bjc.2013.653","volume":"109","author":"P Bonvini","year":"2013","unstructured":"Bonvini, P. et al. High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma. Br. J. Cancer 109, 3084\u20133091 (2013).","journal-title":"Br. J. Cancer"},{"key":"62979_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/modpathol.2012.222","volume":"26","author":"A Yoshida","year":"2013","unstructured":"Yoshida, A. et al. Anaplastic lymphoma kinase status in rhabdomyosarcomas. Mod. Pathol. 26, 772\u2013781 (2013).","journal-title":"Mod. Pathol."},{"key":"62979_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13046-022-02309-1","volume":"41","author":"M Mazzeschi","year":"2022","unstructured":"Mazzeschi, M., et al. The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. J. Exp. Clin. Cancer Res. 41, 113 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"62979_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/1535-7163.MCT-17-0472","volume":"17","author":"KL Couts","year":"2018","unstructured":"Couts, K. L. et al. ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms. Mol. Cancer Therapeutics 17, 222\u2013231 (2018).","journal-title":"Mol. Cancer Therapeutics"},{"key":"62979_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s43018-022-00438-2","volume":"3","author":"Y-Y Chu","year":"2022","unstructured":"Chu, Y.-Y. et al. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat. Cancer 3, 1211\u20131227 (2022).","journal-title":"Nat. Cancer"},{"key":"62979_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ajpath.2021.06.009","volume":"191","author":"T Matsumoto","year":"2021","unstructured":"Matsumoto, T. et al. Anaplastic lymphoma kinase overexpression is associated with aggressive phenotypic characteristics of ovarian high-grade serous carcinoma. Am. J. Pathol. 191, 1837\u20131850 (2021).","journal-title":"Am. J. Pathol."},{"key":"62979_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/PGP.0000000000000260","volume":"35","author":"S Tang","year":"2016","unstructured":"Tang, S. et al. Aberrant expression of anaplastic lymphoma kinase in ovarian carcinoma independent of gene rearrangement. Int J. Gynecol. Pathol. 35, 337\u2013347 (2016).","journal-title":"Int J. Gynecol. Pathol."},{"key":"62979_CR11","doi-asserted-by":"publisher","first-page":"e09878","DOI":"10.1016\/j.heliyon.2022.e09878","volume":"8","author":"Saifullah, null & Tsukahara, T","year":"2022","unstructured":"Saifullah, null & Tsukahara, T Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers. Heliyon 8, e09878 (2022).","journal-title":"Heliyon"},{"key":"62979_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0610-3","volume":"17","author":"AK Siraj","year":"2015","unstructured":"Siraj, A. K. et al. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res. 17, 127 (2015).","journal-title":"Breast Cancer Res"},{"key":"62979_CR13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nature07397","volume":"455","author":"RE George","year":"2008","unstructured":"George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975\u2013978 (2008).","journal-title":"Nature"},{"key":"62979_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nature07399","volume":"455","author":"Y Chen","year":"2008","unstructured":"Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971\u2013974 (2008).","journal-title":"Nature"},{"key":"62979_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.78","volume":"2","author":"KK Matthay","year":"2016","unstructured":"Matthay, K. K. et al. Neuroblastoma. Nat. Rev. Dis. Prim. 2, 16078 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"62979_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2019.11642","volume":"322","author":"JR Park","year":"2019","unstructured":"Park, J. R. et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 322, 746\u2013755 (2019).","journal-title":"JAMA"},{"key":"62979_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/children5090114","volume":"5","author":"V Smith","year":"2018","unstructured":"Smith, V. & Foster, J. High-risk neuroblastoma treatment review. Children 5, 114 (2018).","journal-title":"Children"},{"key":"62979_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29537","volume":"69","author":"WL Hobbie","year":"2022","unstructured":"Hobbie, W. L. et al. Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation. Pediatr. Blood Cancer 69, e29537 (2022).","journal-title":"Pediatr. Blood Cancer"},{"key":"62979_CR19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1078-0432.CCR-21-2451","volume":"28","author":"B Spitzer","year":"2022","unstructured":"Spitzer, B. et al. Bone marrow surveillance of pediatric cancer survivors identifies clones that predict therapy-related leukemia. Clin. Cancer Res. 28, 1614\u20131627 (2022).","journal-title":"Clin. Cancer Res"},{"key":"62979_CR20","doi-asserted-by":"crossref","unstructured":"Berko, E. R. et al. Frequency and clinical significance of clonal and subclonal driver mutations in high-risk neuroblastoma at diagnosis: a children\u2019s oncology group study. J. Clin. Oncol. 43, 02407 (2025).","DOI":"10.1200\/JCO-24-02407"},{"key":"62979_CR21","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-15-0423","volume":"21","author":"A Bellini","year":"2015","unstructured":"Bellini, A. et al. Deep sequencing reveals occurrence of subclonal alk mutations in neuroblastoma at diagnosis. Clin. Cancer Res. 21, 4913\u20134921 (2015).","journal-title":"Clin. Cancer Res."},{"key":"62979_CR22","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-09-2660","volume":"16","author":"S De Brouwer","year":"2010","unstructured":"De Brouwer, S. et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16, 4353\u20134362 (2010).","journal-title":"Clin. Cancer Res."},{"key":"62979_CR23","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1200\/JCO.2013.54.0674","volume":"32","author":"G Schleiermacher","year":"2014","unstructured":"Schleiermacher, G. et al. Emergence of new ALK mutations at relapse of neuroblastoma. J. Clin. Oncol. 32, 2727\u20132734 (2014).","journal-title":"J. Clin. Oncol."},{"key":"62979_CR24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/ng.3333","volume":"47","author":"TF Eleveld","year":"2015","unstructured":"Eleveld, T. F. et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat. Genet 47, 864\u2013871 (2015).","journal-title":"Nat. Genet"},{"key":"62979_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/2159-8290.CD-15-1056","volume":"6","author":"NR Infarinato","year":"2016","unstructured":"Infarinato, N. R. et al. The ALK\/ROS1 Inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov. 6, 96\u2013107 (2016).","journal-title":"Cancer Discov."},{"key":"62979_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","volume":"26","author":"SC Bresler","year":"2014","unstructured":"Bresler, S. C. et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 26, 682\u2013694 (2014).","journal-title":"Cancer Cell"},{"key":"62979_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Moss\u00e9","year":"2013","unstructured":"Moss\u00e9, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472\u2013480 (2013).","journal-title":"Lancet Oncol."},{"key":"62979_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41591-023-02297-5","volume":"29","author":"KC Goldsmith","year":"2023","unstructured":"Goldsmith, K. C. et al. Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results. Nat. Med. 29, 1092\u20131102 (2023).","journal-title":"Nat. Med"},{"key":"62979_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9732","volume":"11","author":"R Sano","year":"2019","unstructured":"Sano, R. et al. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Sci. Transl. Med. 11, eaau9732 (2019).","journal-title":"Sci. Transl. Med"},{"key":"62979_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/ajcp\/aqac172","volume":"159","author":"N Bhardwaj","year":"2023","unstructured":"Bhardwaj, N. et al. ALK gene mutation and ALK protein expression in advanced neuroblastoma and the potential value in risk stratification in fine-needle aspiration biopsy samples. Am. J. Clin. Pathol. 159, 407\u2013415 (2023).","journal-title":"Am. J. Clin. Pathol."},{"key":"62979_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4132\/jptm.2023.12.07","volume":"58","author":"TDA Phan","year":"2024","unstructured":"Phan, T. D. A., Nguyen, T. Q., To, N. T., Thanh, T. L. & Ngo, D. Q. Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features. J. Pathol. Transl. Med. 58, 29\u201334 (2024).","journal-title":"J. Pathol. Transl. Med"},{"key":"62979_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer, M. J., Moore, K. N., Betella, I. & Bates, R. C. Antibody-drug conjugate-based therapeutics: state of the science. J. Natl. Cancer Inst. 111, 538\u2013549 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"62979_CR33","doi-asserted-by":"crossref","unstructured":"Rubahamya, B., Dong, S. & Thurber, G. M. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv 10, eadk1894 (2024).","DOI":"10.1126\/sciadv.adk1894"},{"key":"62979_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2125.2008.03187.x","volume":"66","author":"BW Newsome","year":"2008","unstructured":"Newsome, B. W. & Ernstoff, M. S. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br. J. Clin. Pharm. 66, 6\u201319 (2008).","journal-title":"Br. J. Clin. Pharm."},{"key":"62979_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","volume":"21","author":"JA Hartley","year":"2021","unstructured":"Hartley, J. A. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin. Biol. Ther. 21, 931\u2013943 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"62979_CR36","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/1759-7714.15445","volume":"15","author":"YE Sung","year":"2024","unstructured":"Sung, Y. E. & Kim, M. Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation. Thorac. Cancer 15, 2175\u20132184 (2024).","journal-title":"Thorac. Cancer"},{"key":"62979_CR37","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1200\/JCO.21.00278","volume":"39","author":"MS Irwin","year":"2021","unstructured":"Irwin, M. S. et al. Revised neuroblastoma risk classification system: a report from the children\u2019s oncology group. J. Clin. Oncol. 39, 3229\u20133241 (2021).","journal-title":"J. Clin. Oncol."},{"key":"62979_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-021-04141-7","volume":"600","author":"T Li","year":"2021","unstructured":"Li, T. et al. Structural basis for ligand reception by anaplastic lymphoma kinase. Nature 600, 148\u2013152 (2021).","journal-title":"Nature"},{"key":"62979_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jim.2012.02.017","volume":"379","author":"M Dysinger","year":"2012","unstructured":"Dysinger, M. & King, L. E. Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic. J. Immunol. Methods 379, 30\u201341 (2012).","journal-title":"J. Immunol. Methods"},{"key":"62979_CR40","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1093\/emboj\/16.11.2985","volume":"16","author":"WA Weiss","year":"1997","unstructured":"Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G. & Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985\u20132995 (1997).","journal-title":"EMBO J."},{"key":"62979_CR41","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1158\/1535-7163.MCT-20-1034","volume":"20","author":"S Buongervino","year":"2021","unstructured":"Buongervino, S. et al. Antibody-drug conjugate efficacy in neuroblastoma: role of payload, resistance mechanisms, target density, and antibody internalization. Mol. Cancer Ther. 20, 2228\u20132239 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"62979_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37215-3","volume":"14","author":"B Trastoy","year":"2023","unstructured":"Trastoy, B. et al. Mechanism of antibody-specific deglycosylation and immune evasion by Streptococcal IgG-specific endoglycosidases. Nat. Commun. 14, 1705 (2023).","journal-title":"Nat. Commun."},{"key":"62979_CR43","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/0008-5472.CAN-14-0013","volume":"74","author":"D Mouradov","year":"2014","unstructured":"Mouradov, D. et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 74, 3238\u20133247 (2014).","journal-title":"Cancer Res."},{"key":"62979_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.996053","volume":"13","author":"Y Qi","year":"2022","unstructured":"Qi, Y. et al. Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS\/ERK pathway. Front Pharm. 13, 996053 (2022).","journal-title":"Front Pharm."},{"key":"62979_CR45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-22-2274","volume":"29","author":"ER Tucker","year":"2023","unstructured":"Tucker, E. R. et al. Combination therapies targeting ALK-aberrant neuroblastoma in preclinical models. Clin. Cancer Res. 29, 1317\u20131331 (2023).","journal-title":"Clin. Cancer Res"},{"key":"62979_CR46","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/mt.2011.54","volume":"19","author":"DD Paolo","year":"2011","unstructured":"Paolo, D. D. et al. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol. Ther. 19, 1131 (2011).","journal-title":"Mol. Ther."},{"key":"62979_CR47","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","volume":"25","author":"U Hafeez","year":"2020","unstructured":"Hafeez, U., Parakh, S., Gan, H. K. & Scott, A. M. Antibody\u2013drug conjugates for cancer therapy. Molecules 25, 4764 (2020).","journal-title":"Molecules"},{"key":"62979_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004445","volume":"10","author":"J Hochberg","year":"2022","unstructured":"Hochberg, J. et al. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin\u2019s lymphoma: a phase II, non-randomized controlled trial. J. Immunother. Cancer 10, e004445 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"62979_CR49","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard, J. A. et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children\u2019s Oncology Group Trial AAML0531. J. Clin. Oncol. 39, 3149\u20133160 (2021).","journal-title":"J. Clin. Oncol."},{"key":"62979_CR50","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ccell.2024.10.003","volume":"42","author":"AK Hamilton","year":"2024","unstructured":"Hamilton, A. K. et al. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell 42, 1970\u20131982.e7 (2024).","journal-title":"Cancer Cell"},{"key":"62979_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nri3391","volume":"13","author":"R Shechter","year":"2013","unstructured":"Shechter, R., London, A. & Schwartz, M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat. Rev. Immunol. 13, 206\u2013218 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"62979_CR52","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22, 790\u2013800 (2021).","journal-title":"Lancet Oncol."},{"key":"62979_CR53","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li, F. et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 76, 2710\u20132719 (2016).","journal-title":"Cancer Res."},{"key":"62979_CR54","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers12102912","volume":"12","author":"L Blavier","year":"2020","unstructured":"Blavier, L., Yang, R.-M. & DeClerck, Y. A. The tumor microenvironment in neuroblastoma: new players, new mechanisms of interaction and new perspectives. Cancers 12, 2912 (2020).","journal-title":"Cancers"},{"key":"62979_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156","volume":"133","author":"HL Chang","year":"2023","unstructured":"Chang, H. L., Schwettmann, B., McArthur, H. L. & Chan, I. S. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J. Clin. Invest 133, e172156 (2023).","journal-title":"J. Clin. Invest"},{"key":"62979_CR56","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.3390\/cancers14246249","volume":"14","author":"A Mastronuzzi","year":"2022","unstructured":"Mastronuzzi, A. et al. Central nervous system metastasis in neuroblastoma: from three decades clinical experience to new considerations in the immunotherapy era. Cancers 14, 6249 (2022).","journal-title":"Cancers"},{"key":"62979_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26636-6","volume":"8","author":"S Tiwary","year":"2018","unstructured":"Tiwary, S. et al. Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci. Rep. 8, 8267 (2018).","journal-title":"Sci. Rep."},{"key":"62979_CR58","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch, R. et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat. Med 28, 1840\u20131847 (2022).","journal-title":"Nat. Med"},{"key":"62979_CR59","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"62979_CR60","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189\u20132201 (2017).","journal-title":"Mol. Ther."},{"key":"62979_CR61","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nri856","volume":"2","author":"T Takai","year":"2002","unstructured":"Takai, T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2, 580\u2013592 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"62979_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama, M., Tada, M., Yokoo, H., Demizu, Y. & Ishii-Watabe, A. Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm. Res. 39, 89\u2013103 (2022).","journal-title":"Pharm. Res."},{"key":"62979_CR63","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/acs.jmedchem.2c01812","volume":"66","author":"W Shi","year":"2023","unstructured":"Shi, W. et al. Hiding payload inside the IgG Fc cavity significantly enhances the therapeutic index of antibody-drug conjugates. J. Med Chem. 66, 1011\u20131026 (2023).","journal-title":"J. Med Chem."},{"key":"62979_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.33","volume":"4","author":"JL Harenza","year":"2017","unstructured":"Harenza, J. L. et al. Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci. Data 4, 170033 (2017).","journal-title":"Sci. Data"},{"key":"62979_CR65","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858\u20135868 (1998).","journal-title":"J. Biol. Chem."},{"key":"62979_CR66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/jmg.2009.066944","volume":"46","author":"S Ghavami","year":"2009","unstructured":"Ghavami, S. et al. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 46, 497\u2013510 (2009).","journal-title":"J. Med. Genet."},{"key":"62979_CR67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-0716-2433-3_6","volume":"2519","author":"I Alshiraihi","year":"2023","unstructured":"Alshiraihi, I. & Kato, T. A. Apoptosis detection assays. Methods Mol. Biol. 2519, 53\u201363 (2023).","journal-title":"Methods Mol. Biol."},{"key":"62979_CR68","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop, I. E. et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, Phase I\/II Trial. J. Clin. Oncol. 41, 5550\u20135560 (2023).","journal-title":"J. Clin. Oncol."},{"key":"62979_CR69","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.21.00086","volume":"39","author":"A Bellini","year":"2021","unstructured":"Bellini, A. et al. Frequency and prognostic impact of ALK amplifications and mutations in the european neuroblastoma study group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1). J. Clin. Oncol. 39, 3377\u20133390 (2021).","journal-title":"J. Clin. Oncol."},{"key":"62979_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27257","volume":"65","author":"JW Lee","year":"2018","unstructured":"Lee, J. W. et al. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma. Pediatr. Blood Cancer 65, e27257 (2018).","journal-title":"Pediatr. Blood Cancer"},{"key":"62979_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-2-25","volume":"2","author":"AD Marshall","year":"2012","unstructured":"Marshall, A. D. & Grosveld, G. C. Alveolar rhabdomyosarcoma \u2013 the molecular drivers of PAX3\/7-FOXO1-induced tumorigenesis. Skelet. Muscle 2, 25 (2012).","journal-title":"Skelet. Muscle"},{"key":"62979_CR72","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1002\/cam4.2504","volume":"8","author":"E Hibbitts","year":"2019","unstructured":"Hibbitts, E. et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the Children\u2019s Oncology Group. Cancer Med. 8, 6437\u20136448 (2019).","journal-title":"Cancer Med."},{"key":"62979_CR73","first-page":"109","volume":"36","author":"NV Bathula","year":"2021","unstructured":"Bathula, N. V., Bommadevara, H. & Hayes, J. M. Nanobodies: the future of antibody-based immune therapeutics. Cancer Biother Radiopharm. 36, 109\u2013122 (2021).","journal-title":"Cancer Biother Radiopharm."},{"key":"62979_CR74","doi-asserted-by":"publisher","first-page":"e1164919","DOI":"10.1080\/2162402X.2016.1164919","volume":"5","author":"M Kroesen","year":"2016","unstructured":"Kroesen, M. et al. Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. Oncoimmunology 5, e1164919 (2016).","journal-title":"Oncoimmunology"},{"key":"62979_CR75","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park, K. et al. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J. Clin. Oncol. 39, 3391\u20133402 (2021).","journal-title":"J. Clin. Oncol."},{"key":"62979_CR76","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.3390\/molecules28217389","volume":"28","author":"B McNamara","year":"2023","unstructured":"McNamara, B., Greenman, M., Pebley, N., Mutlu, L. & Santin, A. D. Antibody-drug conjugates (ADC) in HER2\/neu-positive gynecologic tumors. Molecules 28, 7389 (2023).","journal-title":"Molecules"},{"key":"62979_CR77","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2767-9764.CRC-22-0137","volume":"2","author":"K Krytska","year":"2022","unstructured":"Krytska, K. et al. Evaluation of the DLL3-targeting antibody\u2013drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma. Cancer Res. Commun. 2, 616\u2013623 (2022).","journal-title":"Cancer Res. Commun."},{"key":"62979_CR78","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/bc500099v","volume":"25","author":"P Strop","year":"2014","unstructured":"Strop, P. Versatility of microbial transglutaminase. Bioconjug Chem. 25, 855\u2013862 (2014).","journal-title":"Bioconjug Chem."},{"key":"62979_CR79","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/jms.1170","volume":"42","author":"J Khoshnoodi","year":"2007","unstructured":"Khoshnoodi, J., Hill, S., Tryggvason, K., Hudson, B. & Friedman, D. B. Identification of N-linked glycosylation sites in human nephrin using mass spectrometry. J. Mass Spectrom. 42, 370\u2013379 (2007).","journal-title":"J. Mass Spectrom."},{"key":"62979_CR80","doi-asserted-by":"publisher","first-page":"eaaq1392","DOI":"10.1126\/science.aaq1392","volume":"360","author":"T-L Liu","year":"2018","unstructured":"Liu, T.-L. et al. Observing the cell in its native state: Imaging subcellular dynamics in multicellular organisms. Science 360, eaaq1392 (2018).","journal-title":"Science"},{"key":"62979_CR81","doi-asserted-by":"publisher","unstructured":"Guerra, A. D. et al. A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers. Github https:\/\/doi.org\/10.5281\/zenodo.15830580 (2025).","DOI":"10.5281\/zenodo.15830580"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62979-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:28:27Z","timestamp":1757392107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62979-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62979"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62979-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7578"}}